微氨基关联受体1激素差异调节多巴胺载体功能
在PubMed上查看摘要
概括
此摘要是机器生成的。微氨基关联受体1 (TAAR1) 激动剂对多巴胺转运体 (DAT) 有不同的作用. 这些TAAR1激动剂如何影响DAT功能和流通的差异对治疗设计具有临床意义.
科学领域
- 神经科学
- 药理学
背景情况
- 包括ulotaront在内的微氨基相关受体1 (TAAR1) 激动剂已被用于神经精神疾病.
- 在III期试验中,Ulotaront的临床抗精神病疗效与安慰剂相似,这引发了关于TAAR1激动机制的问题.
研究的目的
- 在多巴胺转运器 (DAT) 上研究TAAR1激动剂RO5166017,RO5256390和ulotaront的药理学.
- 测试不同的TAAR1激动剂对DAT功能和多巴胺平衡有不同的影响的假设.
主要方法
- 在RO5166017,RO5256390和ulotaront的DAT中评估了直接结合和抑制多巴胺吸收.
- 评估TAAR1对培养细胞和动物突触体的多巴胺吸收和安非他命诱导的多巴胺外流的影响.
- 使用表面生物化来测量细胞表面DAT水平的变化.
主要成果
- RO5166017和RO5256390通过DAT直接抑制了多巴胺吸收,而乌洛坦则没有.
- 在TAAR1依赖的情况下,RO5166017增加了多巴胺吸收,而ULOTARON和RO5256390则降低了多巴胺吸收.
- 细胞表面DAT增加和安非他命诱导的多巴胺外流,效应取决于TAAR1激活.
结论
- 在TAAR1激动剂对DAT的直接和TAAR1中介作用方面存在临床相关的差异.
- 每个激动剂 (RO5166017,RO5256390,ulotaront) 在DAT中显示出独特的药理特征.
- 在TAAR1激动剂的治疗设计和临床应用中,应考虑这些独特的机制.
相关概念视频
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

